Jump to navigation Jump to search
Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist.
History of changes in PMDA indication
- 2022-03-28: Newly indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.).
Also known as
- Generic name: fosanetupitant chloride hydrochloride
- Brand name: Arokaris